| abstract |
The invention relates to a combination of an ACAT inhibitor, for example sulfamic acid, [[2,4,6-tris- (1-methylethyl) phenyl] acetyl] -2,6-bis (1-methylethyl) phenyl ester, and HMG-CoA reductase, for example atorvastatin, which is effective for lipid regulation. The combination increases the reduction of plasma VLDL and LDL cholesterol and increases HDL cholesterol compared to the self-employed inhibitors, which reduces the atherogenic lipoprotein profile. The combination is useful for treating patients with or having an increased risk of developing ischemic syndromes in order to restore endogenous vascular endothelial function. |